Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INNL

(INNL) (INNL) Stock Price, News & Analysis

(INNL) logo

About (INNL) Stock (NASDAQ:INNL)

Advanced Chart

Key Stats

Today's Range
$2.35
$2.35
50-Day Range
N/A
52-Week Range
$0.53
$6.51
Volume
N/A
Average Volume
867,012 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Receive INNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (INNL) and its competitors with MarketBeat's FREE daily newsletter.

INNL Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

INNL Stock Analysis - Frequently Asked Questions

(INNL) (NASDAQ:INNL) issued its quarterly earnings results on Wednesday, August, 17th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.11. The specialty pharmaceutical company had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.04 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that (INNL) investors own include uniQure (QURE), Delcath Systems (DCTHD), NightHawk Biosciences (NHWK), LadRx (CYTR), Eleven Biotherapeutics (EBIO), Immune Pharmaceuticals (IMNP) and Neovasc (NVCN).

Company Calendar

Last Earnings
8/17/2016
Today
6/12/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:INNL
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:INNL) was last updated on 6/13/2025 by MarketBeat.com Staff
From Our Partners